Kathryn Genovese Releases New Book 'Eyes of a Survivor'
August 04, 2022 21:00 ET | Kathryn Genovese, author
AKRON, Ohio, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Kathryn Marie Genovese's book Eyes of a Survivor has been released for readers today.  Kathryn Marie Genovese hails from Ohio, and in this book, she...
CORRECTION - Level Infinite Launches Eastern Mythology-Themed Open-World RPG Chimeraland — Now Available to Play for Free on PC and Mobile Devices
July 21, 2022 09:00 ET | Level Infinite
SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) -- In a release issued July 15, 2022 under the headline "Eastern Mythology-Themed MMORPG Chimeraland is Now Available to Play for Free on PC and...
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
November 18, 2021 14:40 ET | AB Science
PRESS RELEASE AB SCIENCE RECEIVES U.S. FOOD AND DRUG ADMINISTRATION (FDA) AUTHORIZATION TO RESUME PATIENT ENROLMENT IN THE PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) ...
AB Science reçoit l’autorisation de la FDA de reprendre le recrutement des patients dans l'étude confirmatoire de phase 3 du masitinib (AB19001) chez les patients atteints de SLA
November 18, 2021 14:40 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE REÇOIT L'AUTORISATION DE LA FOOD AND DRUG ADMINISTRATION (FDA) AMÉRICAINE DE REPRENDRE LE RECRUTEMENT DE PATIENTS DANS L'ÉTUDE DE PHASE 3 DU MASITINIB DANS LA...
MUMO Studio Launches a Campaign for DUBIUM, a Survival Thriller Game
November 18, 2021 10:56 ET | MUMO Studio
CYPRESS, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- MUMO Studio has launched a Kickstarter campaign today to support the development and help build a community around their debut title, DUBIUM. This...
AB Science annonce aujourd’hui que les dernières données cliniques de survie à long terme dans la SLA seront présentées au colloque international 2021 de la SLA et des maladies du motoneurone
September 02, 2021 11:59 ET | AB Science
COMMUNIQUE DE PRESSE AB SCIENCE PRESENTERA LES DERNIERES DONNEES CLINIQUES DE SURVIE A LONG TERME DANS LA SCLEROSE LATERALE AMYOTROPHIQUE AU COLLOQUE INTERNATIONAL 2021 DE LA SCLEROSE LATERALE...
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
September 02, 2021 11:59 ET | AB Science
PRESS RELEASE AB SCIENCE TO PRESENT LATEST CLINICAL DATA ON LONG-TERM SURVIVAL ANALYSES IN AMYOTROPHIC LATERAL SCLEROSIS AT THE 2021 INTERNATIONAL SYMPOSIUM ON ALS/MND Paris, 2 September, 2021, 6pm...
Resilient Housing Is Needed More Than Ever: But Is It Too Late?
July 28, 2021 10:56 ET | Green Builder Media
Lake City, Colo., July 28, 2021 (GLOBE NEWSWIRE) -- Join Green Builder Media on August 3 at 2:00 pm EDT for the next in its housing-related webinar series: “Why Building and Designing Homes With...
AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo
July 19, 2021 12:12 ET | AB Science
PRESS RELEASE LONG-TERM FOLLOW-UP OF 75 MONTHS SHOWED THAT MASITINIB EXTENDED SURVIVAL IN AMYOTROPHIC LATERAL SCLEROSIS BY 25 MONTHS RELATIVE TO PLACEBO, PROVIDED THAT TREATMENT STARTS EARLY...
AB Science annonce la publication de nouvelles données de survie montrant que le masitinib prolongeait la survie dans la SLA de 25 mois par rapport au placebo
July 19, 2021 12:12 ET | AB Science
COMMUNIQUE DE PRESSE DE NOUVELLES DONNEES À LONG TERME SUR UNE DUREE DE 75 MOIS ONT MONTRÉ QUE LE MASITINIB PROLONGEAIT LA SURVIE DANS LA SCLÉROSE LATÉRALE AMYOTROPHIQUE DE 25 MOIS PAR RAPPORT AU...